Eradivir’s founder, Dr. Philip S. Low, has successfully developed multiple FDA-approved targeted small molecules. These therapies all function by attaching various payloads to ligands, which bind with high specificity to diseased cells. Examples of approved molecules include a radiotherapy drug for prostate cancer and an intraoperative imaging agent for lung and ovarian cancers. Several others are currently in clinical trials (e.g., treatments for cancer, malaria, and sickle cell anemia). Eradivir was founded in March 2020 to advance a promising application of this platform in combating multiple disease states, initially focusing on influenza and other respiratory infections.
Company Details
- Employees
- 22
- Founded
- -
- Address
- West Lafayette, In, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.eradivir.com/
- Keywords
- - Science In Action.
- HQ
- West Lafayette, IN
Eradivir Questions
Eradivir's website is https://www.eradivir.com/
Eradivir's LinkedIn profile is https://www.linkedin.com/company/eradivir
Eradivir has
22 employees.
View email and phone details for 22
employees at Eradivir.
Eradivir's industry is
Biotechnology Research
Eradivir's top competitors are
Mindpeak Gmbh,
On Target Laboratories,
Edwards Lifesciences,
M3 Usa,
Tails Adoption,
Apogee Therapeutics,
Uptrials,
Psi Cro Ag,
Quince Therapeutics,
Low Institute For Therapeutics.
Eradivir's categories are Biotechnology Research
Eradivir's founding year is 2020
